working braincells


strong vision




Cinfa Biotech is part of the Mundipharma global network of independent associated companies, which operates in over 120 countries worldwide. We develop, manufacture and commercialise high-quality biosimilars for oncology and inflammatory diseases.

With our offices in Pamplona, Spain and in Munich, Germany we are committed to highest European quality standards. This forms the basis for addressing the global biosimilars market.

We do our business on a fully integrated level. We cover the entire pharmaceutical value chain from the manufacturing process development to clinical studies; and from regulatory strategy to commercialisation.

Our in-depth technical, clinical, regulatory and commercial expertise and highest European standards ensure the quality of our products. Highly efficient structures in our development and manufacturing processes enable us to quickly progress on our way to market.


Cinfa Biotech is developing highest-quality biosimilars for indications in oncology and inflammatory diseases.

Our lead product candidate Pelmeg® (B12019) is a biosimilar version of Neulasta® (INN: pegfilgrastim) to treat chemotherapy-induced neutropenia. Pegfilgrastim, a granulocyte colony-stimulating factor (G-CSF) receptor agonist, is used to stimulate bone marrow to produce more neutrophils in order to decrease the incidence of infection in patients undergoing chemotherapy.

In September 2018, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for Pelmeg® for the treatment of chemotherapy-induced neutropenia. The marketing authorization application was submitted in September 2017 and is supported by a comprehensive set of biosimilarity data from analytical, biofunctional and clinical studies comparing Pelmeg® and Neulasta®. The clinical development program was based on scientific advice from EMA and included two studies, which confirmed the analytical and biofunctional similarity of Pelmeg® and Neulasta® in highly sensitive clinical study settings.


Are you ready to shape the future of biosimilars? Become part of our innovative expert team!

Our products are created in an unconventionally pleasant working environment. That’s why we are looking for experts who are also renowned for their skills: team players and passionate creators who appreciate working together in an atmosphere of mutual trust and candidness.

If you want to become part of our team please send us your application.

We look forward to meeting you!


Cinfa Biotech S.L.

Travesía de Roncesvalles, 1
E-31699 Olloki (Navarra)


With your consent, the personal data you provide when filling out this form will be processed by Cinfa Biotech S.L., as the party responsible for this website. This information will be used solely for managing and responding to your query. As explained in our Privacy Policy, we guarantee the confidentiality and security of your data, which will not be assigned to third parties for uses other than those previously described and will not be used to send you advertising material. Of course, you can always exercise your rights to access, rectify, limit and suppress the data by writing to us at privacy@mundipharma-biologics.com.